Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Here’s What Happened

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) shares gapped down prior to trading on Thursday . The stock had previously closed at $34.07, but opened at $31.03. Nanobiotix shares last traded at $30.8590, with a volume of 14,146 shares.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on NBTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, January 22nd. Guggenheim raised their price objective on Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday. Finally, TD Cowen reaffirmed a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $25.00.

Nanobiotix Stock Performance

The company’s fifty day moving average is $28.30 and its two-hundred day moving average is $23.40.

Nanobiotix (NASDAQ:NBTX) last released its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The business had revenue of $3.42 million during the quarter. Research analysts forecast that Nanobiotix S.A. – Sponsored ADR will post -1.18 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nanobiotix

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Millennium Management LLC purchased a new position in Nanobiotix in the 4th quarter worth approximately $390,000. Royal Bank of Canada lifted its position in shares of Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after purchasing an additional 2,500 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Nanobiotix during the fourth quarter worth $220,000. Finally, Optiver Holding B.V. purchased a new position in shares of Nanobiotix in the third quarter valued at $101,000. 38.81% of the stock is owned by institutional investors and hedge funds.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.